Three-dimensional conformal radiotherapy for locoregionally recurrent XXXX after external beam irradiation: a prospective phase I-II clinical trial.

@entity1 @entity137 @entity82 @entity4153 @entity138 @entity957 @entity2 @entity1208 @entity420 @entity6937
OBJECTIVES: To observe in a clinical trial the feasibility, tolerance, and efficacy of reirradiation by three-dimensional conformal radiotherapy (3D-CRT) for locoregionally recurrent @entity2 after external beam radiotherapy (EBRT). MATERIALS AND METHODS: Between June 1999 and March 2001, 23 @entity2 @entity1 with locoregional recurrence after EBRT were enrolled in this study. Of the 23 @entity1 , 21 were @entity1 and 2 were @entity1 (median age 68 years, range 43-79). At the first course of @entity138 , 9 @entity1 had @entity957 , 7 @entity420 , and 7 @entity4153 . The interval between the first course of @entity138 and recurrence varied from 6 to 42 months (median 13). The median dose of the first course of @entity138 was 66 Gy (range 30-78). Reirradiation was carried out using 3D-CRT and only covered the radiographic lesions. The median dose of reirradiation was 51 Gy (range 46-60), which was delivered by a conventionally fractionated schedule (i.e., 1.8-2.0 Gy/fraction, 5 fractions/wk). The @entity137 was assessed according to the Radiation Therapy Oncology Group criteria. RESULTS: The median follow-up time was 15 months (range 2-37). Acute @entity1208 occurred in 9% of @entity1 (Grade 1-2). @entity6937 developed in 22% of @entity1 (Grade 1-2). No cases of acute Grade 3 or greater @entity137 had been recorded at last follow-up. Pulmonary @entity82 was observed in 26% of @entity1 (Grade 2-3); no other severe late complications have been observed. The 1- and 2-year survival rate was 59% and 21%, respectively. The locoregional progression-free rate at 1 and 2 years was 51% and 42%, respectively. CONCLUSIONS: Reirradiation using 3D-CRT was tolerated by this group of recurrent @entity2 @entity1 without severe complications. The 2-year outcome was encouraging. Reirradiation with 3D-CRT can be considered an option for the management of locoregionally recurrent @entity2 .
